Astellas Pharma (OTCMKTS:ALPMY) Hits New 12-Month Low at $10.28

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report)'s share price hit a new 52-week low during trading on Monday . The stock traded as low as $10.28 and last traded at $10.52, with a volume of 351426 shares trading hands. The stock had previously closed at $10.60.

Astellas Pharma Price Performance

The company has a market capitalization of $19.18 billion, a PE ratio of 27.18, a price-to-earnings-growth ratio of 1.36 and a beta of 0.32. The company's 50 day simple moving average is $10.94 and its 200 day simple moving average is $11.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.91 and a quick ratio of 0.71.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last posted its quarterly earnings data on Monday, February 5th. The company reported $0.12 earnings per share for the quarter. The business had revenue of $2.86 billion during the quarter. Astellas Pharma had a return on equity of 6.39% and a net margin of 0.08%. As a group, sell-side analysts predict that Astellas Pharma Inc. will post 0.35 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.